Aileron Therapeutics Reports First Quarter 2019 Financial Results
Aileron announced a $26 million capital raise via PIPE transaction Enrollment in Phase 2a expansion cohort testing ALRN-6924 in combination with Pfizer’s IBRANCE® (palbociclib) in MDM2-amplified tumors underway and ahead of schedule ALRN-6924/ …